WO2023042123 - ANTI-CGRP ANTIBODY DOSING AND SCREENING METHODS
National phase entry is expected:
Publication Number
WO/2023/042123
Publication Date
23.03.2023
International Application No.
PCT/IB2022/058723
International Filing Date
15.09.2022
Title **
[English]
ANTI-CGRP ANTIBODY DOSING AND SCREENING METHODS
[French]
PROCÉDÉS DE DOSAGE ET DE CRIBLAGE D'ANTICORPS ANTI-CGRP
Applicants **
H. LUNDBECK A/S
Inventors
CADY, Roger, K.
ANDERSON, Carlton
BRUNNER, Elizabeth
HIRMAN, Joseph
Priority Data
63/244,466
15.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2203 | |
| EPO | Filing, Examination, Granting | 10546 | |
| Japan | Filing, Examination, Granting | 2354 | |
| South Korea | Filing, Examination, Granting | 2523 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,366
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates the use of monoclonal anti-calcitonin gene-related peptide (CORP) antagonist antibodies or anti-CGRP receptor antibodies in subjects that do not respond adequately to a first dose but respond to the second dose.[French]
La présente invention concerne l'utilisation d'anticorps antagonistes monoclonaux dirigés contre le peptide apparenté au gène calcitonine (CORP) ou des anticorps dirigés contre le récepteur CGRP chez des sujets qui ne répondent pas de manière adéquate à une première dose mais qui répondent à la seconde dose.